Updated Jul 16, 2026
Sweeny Nicole has filed 5 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $285K.
Nicole Sweeny is the Chief Commercial Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. She has been involved in the pharmaceutical industry, contributing to the commercialization of innovative therapies.
| Role | Director |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-11 | KALV | KalVista Pharmaceuticals, Inc. | D — Derivative transaction | 59.3K | $0.00 | |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.5K | $26.78 | $40K |
| 2026-05-27 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.9K | $26.78 | $50K |
| 2026-05-26 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.9K | $20.22 | $38K |
| 2026-04-20 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 4.0K | $15.57 | $62K |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2026-02-25 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2025-12-04 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 3.8K | $13.45 | $51K |
| 2025-12-04 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2025-12-04 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — | |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.5K | $13.42 | $20K |
| 2025-08-22 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 5.0K | — | |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | S — Open-market sale | 1.9K | $13.22 | $25K |
| 2025-08-21 | KALV | KalVista Pharmaceuticals, Inc. | M — Option exercise | 6.2K | — |
Nicole Sweeny is the Chief Commercial Officer at KalVista Pharmaceuticals, Inc., a company focused on developing oral therapies for rare diseases. She has been involved in the pharmaceutical industry, contributing to the commercialization of innovative therapies.…
5 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 7 open-market sales ($285K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Sweeny Nicole profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.